Expansion Strategy

From Clinic to Category.

A five-year plan to build the precision wellness category. Phase 1 validates the model through practitioners. Each subsequent phase is triggered by proven metrics, not arbitrary timelines.

Phase 1

B2B2C Foundation

Phase 2

DTC Expansion

Phase 3

Product Line

Phase 1Q2 2026 to Q1 2027

B2B2C Foundation

The pre-seed funded phase. Prove the model works through the practitioner channel before scaling. From 20 owned-clinic practitioners to 400 across the VUIM alumni network. Validate retention, prove unit economics, and build the data foundation.

Practitioners

20 400

VUIM alumni network activation

Trial-to-Paid

22.5%

Base case conversion rate

Exit MRR

$410K

Monthly recurring revenue target

Subscribers

5,316

Active paying subscribers

Phase 2Year 2

DTC Expansion

With 12 months of validated retention data, Mere opens the direct-to-consumer channel. Ring introduction at metric gate. Paid acquisition launches with clinic-proven content assets. Content-led growth from practitioner UGC.

Target Subscribers

0+

Channel Mix

B2B2C + DTC

Mere App

Native mobile app with subscription management, protocol tracking, biometric dashboard, and direct ordering. Retention-focused with push notifications and refill reminders.

E-Commerce

Direct website sales with subscription-first architecture. Content-led acquisition funnel powered by practitioner case studies and clinical outcomes from Phase 1.

Marketplace

Amazon and wellness retailer presence for discovery and brand awareness. Subscription conversion funneled to owned channels for margin preservation and data capture.

Referral Program

Subscriber-to-subscriber referral with credits. Practitioner UGC and patient testimonials from Phase 1 serve as organic marketing assets. Lower CAC than paid acquisition.

Phase 3Year 3 to 4

Product Line Expansion

Beyond TCM. New protocol families expand Mere's addressable market while leveraging the same platform infrastructure, manufacturing relationship, and AI personalization engine.

Target Subscribers

0+

Protocol Families

4+

Ayurvedic Protocols

Partnership with Ayurvedic institutions to develop NanoActives formulations for Ayurvedic herbal compounds. Same micro-bead technology, new ingredient families.

Functional Nutrition

Western functional medicine protocols targeting specific biomarker optimization. Bridges TCM and Western frameworks for broader practitioner appeal.

Pediatric Protocols

Age-appropriate formulations and dosing for children. Requires additional clinical validation and modified delivery formats. High demand from integrative pediatricians.

Senior Wellness

Protocols optimized for age-related wellness support. Polypharmacy-aware formulations with enhanced herb-drug interaction checking for complex medication profiles.

Phase 4Year 4 to 5

Platform Economics

Mere transitions from a product company to a platform. Data monetization, clinical research partnerships, and white-label protocols create new revenue streams that leverage the infrastructure built in Phases 1 through 3.

Year 4+

Data Licensing

Anonymized outcomes data linking TCM interventions to measurable biometric changes. Pharmaceutical companies, academic researchers, and insurance actuaries are target buyers.

Year 4+

White-Label

Health systems deploying Mere protocols under their own brand. Hospital wellness programs, corporate health plans, and integrative medicine networks.

Year 5+

API Access

Third-party wellness apps and platforms integrating Mere protocol recommendations and biometric analysis. Revenue per API call with volume pricing.

Year 3+

Research Partnerships

Sponsored clinical studies using Mere infrastructure. Pharmaceutical companies pay to test supplement-drug interactions or complementary therapy protocols.

Year 5 Vision

Category-Defining Platform

By Year 5, Mere aims to be the precision wellness standard. 100,000+ subscribers. A global practitioner network spanning multiple traditions. And the world's largest proprietary dataset linking natural interventions to measurable health outcomes.

0+

Active Subscribers

0+

Global Practitioners

0+

Protocol Families

0+

Countries

The Proprietary Dataset

At 100,000+ subscribers with continuous biometric monitoring, Mere will have accumulated millions of data points linking specific natural interventions to measurable physiological changes. No equivalent dataset exists in integrative medicine. This data is the ultimate moat: it improves with scale, it cannot be replicated without the same infrastructure, and its value compounds over time.

The dataset powers every revenue stream: better AI personalization improves subscriber retention, richer data commands higher licensing fees, stronger outcomes evidence drives white-label adoption, and published research attracts practitioner and institutional partnerships. Each subscriber makes the platform more valuable for every other subscriber.

See the Numbers Behind the Vision

Explore the financial model that underpins Phase 1, or review the return scenarios for pre-seed investors.